Revenio Group Oyj is a global medical technology company focused on eye care diagnostic solutions. The company's business model revolves around the development, manufacturing, and commercialization of instruments and software that assist healthcare professionals in diagnosing and monitoring eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). Revenio's product portfolio is anchored by its iCare brand, which features a range of tonometers (such as the iCare IC100, IC200, and HOME2) that measure intraocular pressure without the need for anesthetic drops. The company also offers imaging devices, including the iCare EIDON fundus imaging systems, DRSplus for diabetic retinopathy detection, and iCare COMPASS perimeters.
In addition to hardware, Revenio has been expanding its software and artificial intelligence capabilities, offering solutions like iCare ILLUME for AI-assisted screening, iCare CLINIC for cloud-based data storage, and the Oculo software platform for clinical communication, telehealth, and remote patient monitoring. The company generates revenue through the sale of these diagnostic devices, recurring software subscriptions, and related accessories. Geographically, Revenio operates on a global scale, with the United States and Europe representing its largest markets, alongside growing footprints in the Asia-Pacific region. The company's competitive position is supported by its patented measurement technologies, established brand presence in the ophthalmic community, and recurring revenue streams from software and device accessories.
